{
  "source": "PA-Med-Nec-Intrarosa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2242-5\nProgram Prior Authorization/Medical Necessity\nMedication Intrarosa® (prasterone)\nP&T Approval Date 6/2021, 6/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nImvexxy® (estradiol) vaginal insert, Intrarosa (prasterone) vaginal insert, Osphena®\n(ospemifene) oral tablet, and Premarin® (conjugated estrogens) vaginal cream are\nindicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and\nvaginal atrophy (VVA), due to menopause. Osphena is also indicated for the treatment of\nmoderate to severe vaginal dryness, a symptom of VVA, due to menopause and Premarin\nvaginal cream is indicated for the treatment of atrophic vaginitis and kraurosis vulvae.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Intrarosa will be approved based on all of the following criteria*:\na. Diagnosis of moderate to severe dyspareunia\n- AND-\nb. Patient has vulvar and vaginal atrophy due to menopause\n-AND-\nc. History of failure, contraindication, or intolerance to two of the following:\n1) Imvexxy (estradiol)\n2) Osphena (ospemifene)\n3) Premarin vaginal cream\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Intrarosa will be approved based on the following criterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\n© 2025 UnitedHealthcare Services Inc.\n1\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n* Coverage of medications for the treatment dyspareunia is based on benefit design. Please refer to\nmember’s specific benefits for coverage determination.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and",
    "itional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Imvexxy [package insert]. Boca Raton, FL: TherapeuticsMD, Inc.; November 2023.\n2. Intrarosa [package insert]. East Hanover, NJ: Millicent U.S. Inc.; November 2020.\n3. Osphena [package insert]. Princeton, NJ: Duchesnay USA, Inc.; February 2025.\n4. Premarin cream [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals LLC;\nFebruary 2024.\n5. The 2020 genitourinary syndrome of menopause position statement of The North\nAmerican Menopause Society. Menopause: The Journal of The North American\nMenopause Society. 2020: 27(9); 976-92.\nProgram Prior Authorization/Medical Necessity – Intrarosa\nChange Control\nDate Change\n6/2021 New program\n6/2022 Annual review. Updated references.\n6/2023 Annual review. Updated references & realigned numbering.\n6/2024 Annual review. Updated references.\n6/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}